Page last updated: 2024-12-05

ns 2028

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

NS 2028: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID4551
CHEMBL ID507122
MeSH IDM0288173

Synonyms (49)

Synonym
8-bromo-4h-[1,2,4]oxadiazolo[3,4-c][1,4]benzoxazin-1-one
EU-0100922
ns 2028, solid
LOPAC0_000922
lopac-n-211
NCGC00015722-01
8-bromo-1h,4h-[1,2,4]oxadiazolo[3,4-c][1,4]benzoxazin-1-one
4h-8-bromo-1,2,4-oxadiazolo(3,4-d)benz(b)(1,4)oxazin-1-one
ns 2028
NCGC00094233-02
NCGC00094233-01
NCGC00015722-02
N-211
NCGC00015722-04
EC-000.2278
204326-43-2
ns-2028 ,
CHEMBL507122
HMS3262J06
8-bromobenzo[b][1,2,4]oxadiazolo[4,3-d][1,4]oxazin-1(4h)-one
28N ,
CCG-205004
NCGC00015722-03
BRD-K03645807-001-01-7
LP00922
bdbm113770
ns2028 (1)
ns2028
gtpl6554
tox21_500922
NCGC00261607-01
AKOS024458199
HMS3649M06
SR-01000075533-1
sr-01000075533
4-h-bromo-1,2,4-oxadiazole(3,4-alpha)benz(b)oxazin-1-one
Q27088053
SR-01000075533-5
DTXSID901017568
unii-ku8k3g4867
8-bromo-1h,4h-(1,2,4)oxadiazolo(3,4-c)(1,4)benzoxazin-1-one
ku8k3g4867 ,
1h,4h-(1,2,4)oxadiazolo(3,4-c)(1,4)benzoxazin-1-one, 8-bromo-
1h,4h-[1,2,4]oxadiazolo[3,4-c][1,4]benzoxazin-1-one, 8-bromo-
SDCCGSBI-0050897.P002
CS-0011196
HY-12379
MS-23799
8-bromo-1h,4h-benzo[b][1,2,4]oxadiazolo[4,3-d][1,4]oxazin-1-one

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" ODQ (1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one), a potent and selective inhibitor of soluble guanylyl cyclase (sGC), did not significantly affect relaxant actions of ONOO-, but ODQ markedly attenuated SIN-1-elicited relaxation with a rightward shift in the dose-response curve and an unaltered maximal response."( Comparative vasodilation of peroxynitrite and 3-morpholinosydnonimine.
Trakranrungsie, N; Will, JA, 2001
)
0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (33)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency19.95260.004023.8416100.0000AID485290
USP1 protein, partialHomo sapiens (human)Potency0.63100.031637.5844354.8130AID504865
GLS proteinHomo sapiens (human)Potency3.98110.35487.935539.8107AID624146
thyroid stimulating hormone receptorHomo sapiens (human)Potency6.30960.001318.074339.8107AID926
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency0.02240.035520.977089.1251AID504332
Bloom syndrome protein isoform 1Homo sapiens (human)Potency398.10700.540617.639296.1227AID2364; AID2528
cellular tumor antigen p53 isoform aHomo sapiens (human)Potency7.94330.316212.443531.6228AID902
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency100.00000.354828.065989.1251AID504847
chromobox protein homolog 1Homo sapiens (human)Potency89.12510.006026.168889.1251AID488953
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency5.62340.01789.637444.6684AID588834
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency19.95260.031610.279239.8107AID884; AID885
M-phase phosphoprotein 8Homo sapiens (human)Potency10.00000.177824.735279.4328AID488949
lamin isoform A-delta10Homo sapiens (human)Potency0.00090.891312.067628.1838AID1487
pyruvate kinase PKM isoform bHomo sapiens (human)Potency0.01262.511912.262825.1189AID954; AID958
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Atrial natriuretic peptide receptor 1Homo sapiens (human)IC50 (µMol)0.03600.00600.02100.0360AID340322
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (16)

Processvia Protein(s)Taxonomy
cGMP biosynthetic processAtrial natriuretic peptide receptor 1Homo sapiens (human)
cell surface receptor signaling pathwayAtrial natriuretic peptide receptor 1Homo sapiens (human)
receptor guanylyl cyclase signaling pathwayAtrial natriuretic peptide receptor 1Homo sapiens (human)
G protein-coupled receptor signaling pathwayAtrial natriuretic peptide receptor 1Homo sapiens (human)
body fluid secretionAtrial natriuretic peptide receptor 1Homo sapiens (human)
regulation of blood pressureAtrial natriuretic peptide receptor 1Homo sapiens (human)
positive regulation of cGMP-mediated signalingAtrial natriuretic peptide receptor 1Homo sapiens (human)
negative regulation of angiogenesisAtrial natriuretic peptide receptor 1Homo sapiens (human)
cGMP-mediated signalingAtrial natriuretic peptide receptor 1Homo sapiens (human)
negative regulation of cell growthAtrial natriuretic peptide receptor 1Homo sapiens (human)
positive regulation of urine volumeAtrial natriuretic peptide receptor 1Homo sapiens (human)
positive regulation of renal sodium excretionAtrial natriuretic peptide receptor 1Homo sapiens (human)
dopamine metabolic processAtrial natriuretic peptide receptor 1Homo sapiens (human)
regulation of vascular permeabilityAtrial natriuretic peptide receptor 1Homo sapiens (human)
negative regulation of smooth muscle cell proliferationAtrial natriuretic peptide receptor 1Homo sapiens (human)
blood vessel diameter maintenanceAtrial natriuretic peptide receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
guanylate cyclase activityAtrial natriuretic peptide receptor 1Homo sapiens (human)
protein kinase activityAtrial natriuretic peptide receptor 1Homo sapiens (human)
ATP bindingAtrial natriuretic peptide receptor 1Homo sapiens (human)
GTP bindingAtrial natriuretic peptide receptor 1Homo sapiens (human)
G protein-coupled peptide receptor activityAtrial natriuretic peptide receptor 1Homo sapiens (human)
natriuretic peptide receptor activityAtrial natriuretic peptide receptor 1Homo sapiens (human)
peptide hormone bindingAtrial natriuretic peptide receptor 1Homo sapiens (human)
hormone bindingAtrial natriuretic peptide receptor 1Homo sapiens (human)
peptide receptor activityAtrial natriuretic peptide receptor 1Homo sapiens (human)
adenylate cyclase activityAtrial natriuretic peptide receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
plasma membraneAtrial natriuretic peptide receptor 1Homo sapiens (human)
ANPR-A receptor complexAtrial natriuretic peptide receptor 1Homo sapiens (human)
receptor complexAtrial natriuretic peptide receptor 1Homo sapiens (human)
plasma membraneAtrial natriuretic peptide receptor 1Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (22)

Assay IDTitleYearJournalArticle
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID340322Inhibition of guanylate cyclase2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity.
AID1800330PvdQ IC50 Assay from Article 10.1021/cb5001586: \\Identification of Inhibitors of PvdQ, an Enzyme Involved in the Synthesis of the Siderophore Pyoverdine.\\2014ACS chemical biology, Jul-18, Volume: 9, Issue:7
Identification of inhibitors of PvdQ, an enzyme involved in the synthesis of the siderophore pyoverdine.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (44)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's5 (11.36)18.2507
2000's16 (36.36)29.6817
2010's17 (38.64)24.3611
2020's6 (13.64)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 16.28

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index16.28 (24.57)
Research Supply Index3.81 (2.92)
Research Growth Index4.91 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (16.28)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other44 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]